Washington Trust’s Immunogen Inc IMGN Stock Holding History

Washington Trust’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-23	Closed	–	–	869
2018 Q2	$0	Buy	+23	New	+$242	﹤0.01%	971

Other funds holding IMGN

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Washington Trust's IMGN Position: Q3 2018 in Review

Washington Trust sold out of Immunogen Inc (IMGN) in Q3 2018, closing a stake of 23 shares.

Washington Trust first reported a position in IMGN in Q2 2018 and held it in 1 quarter. The position peaked at $0 in Q2 2018. 208 funds tracked by Wall St. Rank hold IMGN as of Q3 2018.

Washington Trust reported no remaining Immunogen Inc position as of Q3 2018 after selling out during the quarter.
Washington Trust sold 23 Immunogen Inc shares in Q3 2018.
Washington Trust first reported a position in Immunogen Inc in Q2 2018 and held it in 1 quarter.
Washington Trust's Immunogen Inc position peaked at $0 in Q2 2018.
208 funds tracked by Wall St. Rank held Immunogen Inc as of Q3 2018.

Based on Washington Trust's 13F filing for Q3 2018, filed 13 Nov 2018.